226 related articles for article (PubMed ID: 38811031)
1. Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence.
Werner R; Steinmann N; Decaluwe H; Date H; De Ruysscher D; Opitz I
Eur Respir Rev; 2024 Apr; 33(172):. PubMed ID: 38811031
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic options for oligoprogressive non-small cell lung cancer].
Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
[TBL] [Abstract][Full Text] [Related]
5. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
7. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
8. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy.
Warth A; Macher-Goeppinger S; Muley T; Thomas M; Hoffmann H; Schnabel PA; Penzel R; Schirmacher P; Aulmann S
Eur Respir J; 2012 Jun; 39(6):1437-42. PubMed ID: 22075483
[TBL] [Abstract][Full Text] [Related]
9. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
[TBL] [Abstract][Full Text] [Related]
10. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
[TBL] [Abstract][Full Text] [Related]
11. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.
Franceschini D; De Rose F; Cozzi S; Franzese C; Rossi S; Finocchiaro G; Toschi L; Santoro A; Scorsetti M
Crit Rev Oncol Hematol; 2020 Apr; 148():102894. PubMed ID: 32062314
[TBL] [Abstract][Full Text] [Related]
12. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
Bansal P; Rusthoven C; Boumber Y; Gan GN
Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
14. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Weickhardt AJ; Scheier B; Burke JM; Gan G; Lu X; Bunn PA; Aisner DL; Gaspar LE; Kavanagh BD; Doebele RC; Camidge DR
J Thorac Oncol; 2012 Dec; 7(12):1807-1814. PubMed ID: 23154552
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatment of pulmonary oligorecurrence after curative resection for non-small-cell lung cancer.
Han SJ; Cho S; Yum S; Kim K; Jheon S
Interact Cardiovasc Thorac Surg; 2020 Jan; 30(1):18-23. PubMed ID: 31539023
[TBL] [Abstract][Full Text] [Related]
16. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
[TBL] [Abstract][Full Text] [Related]
17. [The Significance of Surgery for Oligometastatic and Oligoprogressive Non-small Cell Lung Cancer].
Schmid S; Passlick B
Zentralbl Chir; 2017 Sep; 142(S 01):S38-S43. PubMed ID: 28958109
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.
Videtic GMM; Donington J; Giuliani M; Heinzerling J; Karas TZ; Kelsey CR; Lally BE; Latzka K; Lo SS; Moghanaki D; Movsas B; Rimner A; Roach M; Rodrigues G; Shirvani SM; Simone CB; Timmerman R; Daly ME
Pract Radiat Oncol; 2017; 7(5):295-301. PubMed ID: 28596092
[TBL] [Abstract][Full Text] [Related]
19. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
[TBL] [Abstract][Full Text] [Related]
20. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V; Park HS; Decker RH
Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
